1
|
Chambel SS, Cruz CD. Axonal growth inhibitors and their receptors in spinal cord injury: from biology to clinical translation. Neural Regen Res 2023; 18:2573-2581. [PMID: 37449592 DOI: 10.4103/1673-5374.373674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/18/2023] Open
Abstract
Axonal growth inhibitors are released during traumatic injuries to the adult mammalian central nervous system, including after spinal cord injury. These molecules accumulate at the injury site and form a highly inhibitory environment for axonal regeneration. Among these inhibitory molecules, myelin-associated inhibitors, including neurite outgrowth inhibitor A, oligodendrocyte myelin glycoprotein, myelin-associated glycoprotein, chondroitin sulfate proteoglycans and repulsive guidance molecule A are of particular importance. Due to their inhibitory nature, they represent exciting molecular targets to study axonal inhibition and regeneration after central injuries. These molecules are mainly produced by neurons, oligodendrocytes, and astrocytes within the scar and in its immediate vicinity. They exert their effects by binding to specific receptors, localized in the membranes of neurons. Receptors for these inhibitory cues include Nogo receptor 1, leucine-rich repeat, and Ig domain containing 1 and p75 neurotrophin receptor/tumor necrosis factor receptor superfamily member 19 (that form a receptor complex that binds all myelin-associated inhibitors), and also paired immunoglobulin-like receptor B. Chondroitin sulfate proteoglycans and repulsive guidance molecule A bind to Nogo receptor 1, Nogo receptor 3, receptor protein tyrosine phosphatase σ and leucocyte common antigen related phosphatase, and neogenin, respectively. Once activated, these receptors initiate downstream signaling pathways, the most common amongst them being the RhoA/ROCK signaling pathway. These signaling cascades result in actin depolymerization, neurite outgrowth inhibition, and failure to regenerate after spinal cord injury. Currently, there are no approved pharmacological treatments to overcome spinal cord injuries other than physical rehabilitation and management of the array of symptoms brought on by spinal cord injuries. However, several novel therapies aiming to modulate these inhibitory proteins and/or their receptors are under investigation in ongoing clinical trials. Investigation has also been demonstrating that combinatorial therapies of growth inhibitors with other therapies, such as growth factors or stem-cell therapies, produce stronger results and their potential application in the clinics opens new venues in spinal cord injury treatment.
Collapse
Affiliation(s)
- Sílvia Sousa Chambel
- Experimental Biology Unit, Department of Biomedicine, Faculty of Medicine of Porto; Translational NeuroUrology, Instituto de Investigação e Inovação em Saúde-i3S and IBMC, Universidade do Porto, Porto, Portugal
| | - Célia Duarte Cruz
- Experimental Biology Unit, Department of Biomedicine, Faculty of Medicine of Porto; Translational NeuroUrology, Instituto de Investigação e Inovação em Saúde-i3S and IBMC, Universidade do Porto, Porto, Portugal
| |
Collapse
|
2
|
Michel-Flutot P, Vinit S. La stimulation magnétique répétée pour le traitement des traumas spinaux. Med Sci (Paris) 2022; 38:679-685. [DOI: 10.1051/medsci/2022108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Les traumas spinaux induisent des déficits moteurs et sensoriels. La mise au point de thérapies visant à rétablir les fonctions altérées à la suite d’une lésion de la moelle épinière est donc nécessaire. La stimulation magnétique répétée (SMr) est une thérapie innovante et non invasive utilisée pour moduler l’activité de réseaux neuronaux dans diverses maladies neurologiques, telles que la maladie de Parkinson, ou psychiatriques, telles que le trouble bipolaire. Son utilisation chez les personnes atteintes de traumas spinaux pourrait avoir des effets fonctionnels bénéfiques. Des études réalisées in vitro, in vivo et ex vivo ont permis de comprendre en partie les mécanismes sous-jacents à la modulation de l’activité neuronale induite par les protocoles de SMr. Son utilisation dans des modèles précliniques de lésion médullaire a de plus montré des effets bénéfiques fonctionnels. Ainsi, la SMr pourrait potentialiser la récupération des fonctions perdues après un trauma spinal.
Collapse
|
3
|
An enhanced therapeutic effect of repetitive transcranial magnetic stimulation combined with antibody treatment in a primate model of spinal cord injury. PLoS One 2021; 16:e0252023. [PMID: 34077429 PMCID: PMC8172028 DOI: 10.1371/journal.pone.0252023] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Accepted: 05/10/2021] [Indexed: 11/30/2022] Open
Abstract
Repetitive transcranial magnetic stimulation (rTMS) targeting the primary motor cortex (MI) is expected to provide a therapeutic impact on spinal cord injury (SCI). On the other hand, treatment with antibody against repulsive guidance molecule-a (RGMa) has been shown to ameliorate motor deficits after SCI in rodents and primates. Facilitating activity of the corticospinal tract (CST) by rTMS following rewiring of CST fibers by anti-RGMa antibody treatment may exert an enhanced effect on motor recovery in a primate model of SCI. To address this issue, we examined whether such a combined therapeutic strategy could contribute to accelerating functional restoration from SCI. In our SCI model, unilateral lesions were made between the C6 and the C7 level. Two macaque monkeys were used for each of the combined therapy and antibody treatment alone, while one monkey was for rTMS alone. The antibody treatment was continuously carried out for four weeks immediately after SCI, and rTMS trials applying a thermoplastic mask and a laser distance meter lasted ten weeks. Behavioral assessment was performed over 14 weeks after SCI to investigate the extent to which motor functions were restored with the antibody treatment and/or rTMS. While rTMS without the preceding antibody treatment produced no discernible sign for functional recovery, a combination of the antibody and rTMS exhibited a greater effect, especially at an early stage of rTMS trials, on restoration of dexterous hand movements. The present results indicate that rTMS combined with anti-RGMa antibody treatment may exert a synergistic effect on motor recovery from SCI.
Collapse
|
4
|
Repulsive Guidance Molecule-a and Central Nervous System Diseases. BIOMED RESEARCH INTERNATIONAL 2021; 2021:5532116. [PMID: 33997000 PMCID: PMC8112912 DOI: 10.1155/2021/5532116] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Accepted: 04/27/2021] [Indexed: 12/12/2022]
Abstract
Repulsive guidance molecule-a (RGMa) is a member of glycosylphosphatidylinositol- (GPI-) anchored protein family, which has axon guidance function and is widely involved in the development and pathological processes of the central nervous system (CNS). On the one hand, the binding of RGMa and its receptor Neogenin can regulate axonal guidance, differentiation of neural stem cells into neurons, and the survival of these cells; on the other hand, RGMa can inhibit functional recovery of CNS by inhibiting axonal growth. A number of studies have shown that RGMa may be involved in the pathogenesis of CNS diseases, such as multiple sclerosis, neuromyelitis optica spectrum diseases, cerebral infarction, spinal cord injury, Parkinson's disease, and epilepsy. Targeting RGMa can enhance the functional recovery of CNS, so it may become a promising target for the treatment of CNS diseases. This article will comprehensively review the research progression of RGMa in various CNS diseases up to date.
Collapse
|
5
|
Chalfouh C, Guillou C, Hardouin J, Delarue Q, Li X, Duclos C, Schapman D, Marie JP, Cosette P, Guérout N. The Regenerative Effect of Trans-spinal Magnetic Stimulation After Spinal Cord Injury: Mechanisms and Pathways Underlying the Effect. Neurotherapeutics 2020; 17:2069-2088. [PMID: 32856173 PMCID: PMC7851265 DOI: 10.1007/s13311-020-00915-5] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
Spinal cord injury (SCI) leads to a loss of sensitive and motor functions. Currently, there is no therapeutic intervention offering a complete recovery. Here, we report that repetitive trans-spinal magnetic stimulation (rTSMS) can be a noninvasive SCI treatment that enhances tissue repair and functional recovery. Several techniques including immunohistochemical, behavioral, cells cultures, and proteomics have been performed. Moreover, different lesion paradigms, such as acute and chronic phase following SCI in wild-type and transgenic animals at different ages (juvenile, adult, and aged), have been used. We demonstrate that rTSMS modulates the lesion scar by decreasing fibrosis and inflammation and increases proliferation of spinal cord stem cells. Our results demonstrate also that rTSMS decreases demyelination, which contributes to axonal regrowth, neuronal survival, and locomotor recovery after SCI. This research provides evidence that rTSMS induces therapeutic effects in a preclinical rodent model and suggests possible translation to clinical application in humans.
Collapse
Affiliation(s)
- C Chalfouh
- Normandie Univ, UNIROUEN, EA3830 GRHV, 76000, Rouen, France.
- Institute for Research and Innovation in Biomedicine (IRIB), 76000, Rouen, France.
| | - C Guillou
- PISSARO Proteomic Facility, Normandie Univ, UNIROUEN, 76821, Mont-Saint-Aignan, France
- Institute for Research and Innovation in Biomedicine (IRIB), Mont-Saint-Aignan, France
| | - J Hardouin
- PISSARO Proteomic Facility, Normandie Univ, UNIROUEN, 76821, Mont-Saint-Aignan, France
- Institute for Research and Innovation in Biomedicine (IRIB), Mont-Saint-Aignan, France
| | - Q Delarue
- Normandie Univ, UNIROUEN, EA3830 GRHV, 76000, Rouen, France
- Institute for Research and Innovation in Biomedicine (IRIB), 76000, Rouen, France
| | - X Li
- Department of Neurobiology, Care sciences and Society, BioClinicum, Karolinska Institutet, 17164, Stockholm, Sweden
| | - C Duclos
- Normandie Univ, UNIROUEN, EA3830 GRHV, 76000, Rouen, France
- Institute for Research and Innovation in Biomedicine (IRIB), 76000, Rouen, France
| | - D Schapman
- Institute for Research and Innovation in Biomedicine (IRIB), Mont-Saint-Aignan, France
- Normandie Univ, UNIROUEN, SFR IRIB, Plateau PRIMACEN, F-76821, Mont-Saint-Aignan, France
| | - J-P Marie
- Normandie Univ, UNIROUEN, EA3830 GRHV, 76000, Rouen, France
- Institute for Research and Innovation in Biomedicine (IRIB), 76000, Rouen, France
| | - P Cosette
- PISSARO Proteomic Facility, Normandie Univ, UNIROUEN, 76821, Mont-Saint-Aignan, France
- Institute for Research and Innovation in Biomedicine (IRIB), Mont-Saint-Aignan, France
| | - N Guérout
- Normandie Univ, UNIROUEN, EA3830 GRHV, 76000, Rouen, France.
- Institute for Research and Innovation in Biomedicine (IRIB), 76000, Rouen, France.
| |
Collapse
|